Rx&D Welcomes New Board of Directors Chair, Michael Tremblay
Nov 18, 2015, 09:52 ET
MONTREAL, Nov. 18, 2015 /CNW Telbec/ - Today, at the Annual General Meeting of Canada's Research-Based Pharmaceutical Companies (Rx&D), Michael Tremblay, President of Astellas Pharma Canada, Inc. (Astellas) was announced as the next Chair of the Board of Directors by President Russell Williams.
Mr. Tremblay's term marks the association's move to a new model of governance, which will see the new Chair head the Board of Directors for a two-year mandate. Mr. Tremblay will continue the work set by the Board which strives to improve access to innovative medicines for Canadians and stimulate Canada's life sciences ecosystem.
- Michael Tremblay has been President of Astellas Pharma Canada, Inc. for six years, and has 40 years' experience in the innovative pharmaceutical industry in Canada, in the sales and marketing, business development, training and customer relationship management areas.
- He has been a member of the Rx&D Board of Directors for six years.
- He is also on the Board of Directors for CHATS (Community & Home Assistance to Seniors).
"I am honoured to be serving in this role where I will be dedicated to working on the many important initiatives the association is championing. Over the next two years, we will focus on helping Canadians live longer and healthier lives through better access to innovative medicines and vaccines." - Michael Tremblay, President, Astellas Pharma Canada, Inc.
"It is my pleasure to pass the torch to Michael Tremblay to continue the important work of our trade association. I know that he will lead us and champion the goals of the innovative pharmaceutical industry in Canada." - John Helou, Immediate Past Chair of the Board of Directors, Rx&D and President, Pfizer Canada Inc.
"We look forward to working with Michael Tremblay as he leads the association through two years of dedicated focus on improving the life sciences ecosystem in Canada. His leadership will be key in working with our partners and further opening dialogue around healthcare sustainability in this country." - Russell Williams, President, Rx&D
About Canada's Research-Based Pharmaceutical Companies
Canada's Research-Based Pharmaceutical Companies is the national association representing the voice of Canada's innovative pharmaceutical industry. We serve our membership by advocating for policies that enable the discovery, development and delivery of innovative medicines and vaccines to improve the lives of all Canadians. We support our memberships' commitment to being a valued partner in the Canadian healthcare system. We represent more than 50 companies investing over $1-billion in R&D annually, fuelling Canada's knowledge-based economy, while contributing over $3-billion overall to Canada's economy. Guided by our Code of Ethical Practices, we work with governments, private payers, healthcare professionals and stakeholders in a highly ethical manner.
SOURCE Canada's Research-Based Pharmaceutical Companies (Rx&D)
Image with caption: "Michael Tremblay, President of Astellas Pharma Canada, Inc. (CNW Group/Canada's Research-Based Pharmaceutical Companies (Rx&D))". Image available at: http://photos.newswire.ca/images/download/20151113_C4074_PHOTO_EN_544980.jpg
For further information: Sarah Douglas, Media Relations, Rx&D, Telephone: 613-883-7250, E-mail: [email protected]
Share this article